Incorrect password
evipedia.ai Suggest Edit

Nicotinamide Riboside for Health & Longevity

Evidence Review created on 04/26/2026 using AI4L / Opus 4.7

Also known as: NR, Niagen, β-Nicotinamide Riboside, Nicotinamide Riboside Chloride

Motivation

Nicotinamide riboside (vitamin B3 form) is a small molecule the body uses to produce a central cellular fuel and helper coenzyme essential for energy production, DNA repair, and metabolic regulation. Levels of this coenzyme drop with age, a decline tied to reduced mitochondrial efficiency, chronic inflammation, and accelerated biological aging. Because oral nicotinamide riboside reliably restores blood levels of the coenzyme in adults, it has become one of the most extensively studied longevity supplements.

Early animal research generated considerable enthusiasm, with reports of improved metabolic health and modest lifespan extension in rodents. Human trials have produced a more measured picture: supplementation consistently raises the target coenzyme and appears to reduce certain inflammatory markers, but clear benefits for muscle, metabolic, or cognitive endpoints have been harder to demonstrate. New laboratory findings on potential interactions with existing tumors have also introduced fresh safety questions.

This review examines the current human evidence on nicotinamide riboside, the gap between preclinical promise and clinical results, and the evolving safety and quality landscape.

Benefits - Risks - Protocol - Conclusion

A curated selection of high-quality resources providing accessible overviews of nicotinamide riboside biology, clinical evidence, and expert perspectives on NAD+ (nicotinamide adenine dinucleotide, the central coenzyme that nicotinamide riboside is meant to replenish) supplementation.

  • Nicotinamide Riboside - Rhonda Patrick

    A dedicated topic page summarizing NR biology, the NAD+ salvage pathway, mechanistic rationale for supplementation, and a synthesis of human RCTs (randomized controlled trials), with attention to inflammation, mitochondrial function, and aging endpoints.

  • NR Supplements: Wasted Money May Not Be the Only Risk with These Questionable “Anti-aging” Drugs - Peter Attia

    A skeptical analysis weighing the limited human efficacy data against new preclinical findings linking NR to accelerated tumor growth in mouse models of breast cancer, providing an important counter-narrative to industry promotion.

  • How to Slow Aging and Increase Healthspan, with Dr. David Sinclair - Chris Kresser

    An interview with one of the most influential NAD+ researchers, examining why NAD+ precursors such as NR are thought to support healthspan, the rationale for human supplementation, and the broader longevity framework in which NR sits.

  • Nicotinamide Riboside Benefits - Jeff Simmons

    An accessible consumer-oriented review of NR’s mechanism, animal and early human findings, and practical considerations for supplementation, written for a longevity-oriented audience and useful for understanding how NR is positioned in the consumer landscape.

  • Therapeutic Potential of NAD-Boosting Molecules: The In Vivo Evidence - Rajman et al., 2018

    A widely cited narrative review from the Sinclair laboratory at Harvard Medical School covering preclinical evidence for NAD+-boosting molecules including NR and NMN (nicotinamide mononucleotide, a closely related NAD+ precursor), summarizing how NAD+ modulates hundreds of cellular processes from energy metabolism to cell survival, and providing the scientific foundation for the clinical trials that followed.

Andrew Huberman has discussed NR briefly in podcast episodes, but no single dedicated Huberman-platform article or episode focused specifically on nicotinamide riboside was identified.

Grokipedia

Nicotinamide Riboside

A reference article covering NR’s chemistry as a pyridine-nucleoside form of vitamin B3, its biosynthesis and natural food sources, the NRK1/NRK2 (nicotinamide riboside kinases 1 and 2, the enzymes that convert NR toward NAD+) — mediated conversion pathway to NAD+, the regulatory landscape (including GRAS (Generally Recognized as Safe) status), and a summary of human clinical findings on dose, safety, and NAD+ elevation.

Examine

No dedicated Examine.com supplement page exists for nicotinamide riboside.

ConsumerLab

NAD Booster Supplements Review (NAD+/NADH, Nicotinamide Riboside, and NMN)

An independent product testing review evaluating NAD+-boosting supplements including NR, NMN, and NAD+/NADH products, with laboratory verification of label claims, top picks based on third-party analysis, and an updated note that many NR products on the market do not match their stated potency.

Systematic Reviews

A selection of systematic reviews and meta-analyses examining nicotinamide riboside or NAD+ precursor supplementation in humans. Conflict of interest note: A meaningful share of underlying NR primary trials have been funded or supported by NR ingredient suppliers (notably ChromaDex, the maker of Niagen) and finished-product brands (e.g., Elysium Health, Tru Niagen), who have a direct financial interest in positive findings; this should be considered when weighing the evidence below and again in the Conclusion.

Mechanism of Action

Nicotinamide riboside is a pyridine-nucleoside form of vitamin B3 that is converted to NAD+ inside cells via a short, two-enzyme route:

  • NRK1 and NRK2 (nicotinamide riboside kinases 1 and 2, the enzymes that phosphorylate NR) convert NR to NMN (nicotinamide mononucleotide, the immediate phosphorylated NAD+ precursor)
  • NMNAT1-3 (nicotinamide mononucleotide adenylyltransferases, enzymes that catalyze the final step of NAD+ synthesis) then convert NMN to NAD+ by combining it with ATP (adenosine triphosphate, the cell’s energy currency)

This pathway bypasses NAMPT (nicotinamide phosphoribosyltransferase, the rate-limiting enzyme of the conventional NAD+ salvage pathway), which is one reason NR is thought to be an efficient way to raise intracellular NAD+ when NAMPT activity declines with age.

NR enters cells via equilibrative nucleoside transporters and may also be partially metabolized in the gut and liver before reaching target tissues. New evidence from a 2026 head-to-head human comparison (Christen et al., 2026) suggests that a meaningful portion of NR’s circulatory NAD+-raising effect may depend on microbial conversion of NR to nicotinic acid in the gut, after which the Preiss-Handler pathway is engaged systemically. This contrasts with the older textbook model in which intact NR is delivered directly to peripheral tissues, and the relative contributions of these routes are still actively examined.

By replenishing NAD+ pools, NR supplementation supports several longevity-associated pathways:

  • Sirtuins (SIRT1-7, a family of NAD+-dependent enzymes regulating DNA repair, metabolic homeostasis, and stress resistance): NAD+ is a required co-substrate for sirtuin activity, and declining NAD+ with age reduces sirtuin function
  • PARPs (poly-ADP-ribose polymerases, NAD+-consuming enzymes critical for DNA strand-break repair): adequate NAD+ supports genomic integrity
  • CD38 (a NAD+-degrading enzyme whose expression rises with age): age-related CD38 increases are a major driver of NAD+ decline, and NR supplementation helps offset this
  • Mitochondrial function: NAD+ is essential for oxidative phosphorylation and the electron transport chain, and restoring NAD+ levels improves mitochondrial bioenergetics

Key pharmacological properties:

  • Half-life: NR itself is rapidly absorbed and largely cleared from plasma within hours; the resulting whole-blood NAD+ elevation persists for approximately 8–24 hours after a single dose, supporting once-daily dosing
  • Selectivity: NR is a substrate for NAD+ biosynthetic enzymes; it is not a receptor ligand
  • Tissue distribution: Whole-blood and PBMC (peripheral blood mononuclear cell) NAD+ elevation is consistently observed; tissue-level human data are sparser, with preclinical evidence supporting uptake in liver, muscle, and brain
  • Metabolism: Primarily metabolized through the NAD+ biosynthetic and salvage pathways; minor catabolism produces nicotinamide and methylated metabolites that are renally excreted, with emerging evidence for a gut-microbial conversion to nicotinic acid

Historical Context & Evolution

Nicotinamide riboside was first identified in 1944 in milk and yeast, but it remained a biochemical curiosity for decades. Interest in NR as a distinct NAD+ precursor accelerated in 2004, when researchers led by Charles Brenner identified NRK1 and NRK2 as the enzymes that phosphorylate NR to NMN, establishing a dedicated cellular pathway for NR conversion to NAD+.

In the early 2010s, work in the Sinclair, Auwerx, and Brenner laboratories showed that oral NR supplementation in mice could raise tissue NAD+, improve mitochondrial function, support muscle stem cell function, and modestly extend lifespan in elderly animals. These preclinical findings spurred commercial development of NR as a dietary supplement, with Niagen (NR chloride) gaining GRAS (Generally Recognized as Safe) status from the FDA and reaching the consumer market beginning in 2013.

The first human safety and pharmacokinetic trials in 2016–2017 confirmed that oral NR is well tolerated and reliably elevates whole-blood NAD+. Subsequent RCTs through 2020–2025 have shown more mixed efficacy: clear NAD+ elevation, signals of reduced inflammation in specific contexts (e.g., COPD, NAFLD), but largely null results for skeletal muscle outcomes in healthy older adults. Most recently, preclinical work suggesting that NR may accelerate growth of pre-existing tumors in some cancer models has prompted re-evaluation of the safety profile in oncology contexts. The current scientific dialogue thus combines confidence in NR’s biochemical effect with measured caution about which clinical outcomes it actually changes and in whom.

Expected Benefits

A dedicated search for nicotinamide riboside’s benefit profile was performed using PubMed, ClinicalTrials.gov, expert sources, and product reference materials before writing this section. Conflict of interest note: A substantial share of NR clinical-trial and consumer evidence is generated by parties with a direct financial interest in NR’s adoption — including ingredient supplier ChromaDex (Niagen) and finished-product brands (Tru Niagen, Elysium Basis, Niagen+) — who have funded or co-authored a large fraction of the human trials cited below. The benefit claims should be read in that context.

High 🟩 🟩 🟩

NAD+ Level Restoration

Multiple RCTs have consistently shown that oral NR supplementation at 250–2,000 mg/day significantly increases whole-blood and PBMC NAD+ within days to weeks. The 2024 COPD trial (Norheim et al., 2024) reported more than a twofold rise in whole-blood NAD+ on 2 g/day NR, and a 2026 head-to-head comparison (Christen et al., 2026) found NR and NMN comparably elevated circulatory NAD+ over 14 days. The Gallagher et al. (2026) and Lippi et al. (2022) systematic reviews both confirm consistent NAD+ target engagement as the most robust effect of NR supplementation in humans.

Magnitude: Whole-blood NAD+ levels rise approximately 2- to 3-fold above baseline depending on dose and duration in clinical trials.

Medium 🟩 🟩

Reduced Airway and Systemic Inflammation in Specific Conditions

NR has shown an anti-inflammatory effect in two well-conducted RCTs in patients with chronic disease. The Norheim et al. (2024) RCT in stable COPD (chronic obstructive pulmonary disease) showed a roughly 53% reduction in sputum IL-8 (interleukin-8, a key chemokine recruiting neutrophils to the airway) at 6 weeks that persisted 12 weeks after treatment ended. The Dellinger et al. (2023) NAFLD (nonalcoholic fatty liver disease) trial of NR combined with pterostilbene showed reductions in markers of hepatic inflammation. Effects on systemic IL-6 (interleukin-6, a pro-inflammatory cytokine) and CRP (C-reactive protein, a general marker of systemic inflammation) have been more inconsistent.

Magnitude: Sputum IL-8 reduced by approximately 53% at week 6 in COPD; lasting effect at 18-week follow-up. Hepatic inflammation marker reductions of similar order in NAFLD.

Improved Walking Performance in Peripheral Artery Disease

The NICE trial (McDermott et al., 2024) in 90 adults with PAD showed that 6 months of NR (1,000 mg/day) improved 6-minute walking distance (6MWD) by approximately 17.6 meters versus placebo, and by approximately 31 meters in adherent participants. This is the strongest functional benefit signal in the NR clinical literature to date and was corroborated in the Prokopidis et al. (2025) meta-analysis.

Magnitude: Approximately 17.6 m improvement in 6MWD versus placebo; approximately 31 m in adherent participants.

Low 🟩

Reduced Plasma p-Tau217 in Mild Cognitive Decline ⚠️ Conflicted

The Wu et al. (2025) crossover RCT in older adults with subjective cognitive decline or mild cognitive impairment found that 8 weeks of NR (1,000 mg/day) reduced plasma p-Tau217 (phosphorylated tau at threonine 217, a blood biomarker of Alzheimer’s disease pathology) by approximately 7%, while it rose 18% on placebo. Cognitive performance on standard tests was not improved. An earlier RCT in mild cognitive impairment (Orr et al., 2024) and a long-COVID RCT (Wu et al., 2025) likewise showed NAD+ elevation without significant cognitive benefits versus placebo. Whether p-Tau217 reduction alone translates into clinical benefit is uncertain.

Magnitude: p-Tau217 fell approximately 7% on NR versus an 18% rise on placebo; cognition unchanged on conventional tests.

Reduced Arterial Stiffness in Werner Syndrome

The Shoji et al. (2025) double-blind crossover trial in patients with Werner syndrome (a rare progeroid disorder of accelerated aging) found that 26 weeks of NR (1,000 mg/day) significantly improved cardio-ankle vascular index (CAVI, a measure of arterial stiffness), reduced skin ulcer area, and lowered blood creatinine. Whether this generalizes beyond the rare-disease setting is unknown.

Magnitude: Significant CAVI improvement and creatinine decrease versus placebo phase; skin ulcer area decreased.

Endothelial and Blood Pressure Effects ⚠️ Conflicted

A pilot RCT in middle-aged and older adults with hypertension (Lin et al., 2025) reported that NR combined with exercise produced modest signals on blood pressure and vascular function, while earlier work by Martens et al. (2018) showed reductions in systolic blood pressure and arterial stiffness in healthy middle-aged adults on 1 g/day NR. Other trials have not consistently replicated blood-pressure benefits, and the meta-analytic synthesis in this domain remains underpowered.

Magnitude: Approximately 8–10 mmHg systolic reduction in subgroup analyses; not consistent across trials.

Speculative 🟨

Slowed Biological Aging via Epigenetic Markers

Exploratory analyses in the COPD trial (Norheim et al., 2024) reported indications of reduced epigenetic aging and upregulated genome-integrity pathways in the airways with NR. These exploratory signals require confirmation in larger trials with prespecified epigenetic-age endpoints before they can be considered established.

Neuroprotection in Parkinson’s and Other Neurodegenerative Conditions

Preclinical and early human data suggest NR may engage NAD+-dependent neuronal pathways relevant to Parkinson’s disease and other neurodegenerative conditions. A high-dose safety trial (NR-SAFE, Berven et al., 2023) confirmed tolerability of 3,000 mg/day for 4 weeks in Parkinson’s, but functional outcome data are pending in larger trials.

Female Reproductive and Lactation Support

Preclinical findings suggest NR may support oocyte quality and lactation. A Phase 2/3 trial (NCT04614714) in mothers of extremely preterm infants is planned, and clinical evidence in fertility and lactation contexts remains preliminary.

Slowed Friedreich Ataxia Progression

A 2026 single-center 2×2 factorial RCT in Friedreich ataxia (Lin et al., 2026) is examining individualized exercise plus NAD+ precursor supplementation; published findings are limited and this remains an exploratory rare-disease application.

Benefit-Modifying Factors

  • Baseline NAD+ levels: Adults with lower baseline NAD+ — typically those over 50, those with chronic inflammatory or metabolic conditions, or those under chronic physiologic stress — appear to have more headroom to benefit from supplementation. Younger, metabolically healthy individuals with adequate NAD+ may see smaller relative effects.

  • Age: NAD+ decline accelerates from middle age onward, and most positive NR trials have been conducted in adults aged 50+. Functional benefits in healthy younger adults are less well documented.

  • Sex-based differences: Several positive NR trials (e.g., Yoshino-style metabolic trials in postmenopausal women, Werner syndrome data, lactation trials) have been conducted in women only or in mixed cohorts. Sex-stratified efficacy analyses in NR trials remain limited, and any meaningful sex differences in human response are not yet well characterized.

  • Disease context: NR’s most robust functional benefits have appeared in disease populations (PAD, COPD, NAFLD, Werner syndrome) rather than in healthy aging cohorts. Whether the magnitude of benefit translates to community-dwelling healthy adults is unclear.

  • Genetic polymorphisms: Variants in NRK1, NRK2, NAMPT, SIRT1, and CD38 may theoretically modulate the efficiency with which NR is converted to NAD+ and used by downstream enzymes, though direct evidence linking specific variants to response in humans is limited.

  • Gut microbiome composition: New 2026 evidence (Christen et al.) suggests microbial conversion of NR to nicotinic acid contributes to systemic NAD+ elevation. Inter-individual differences in microbiome composition may therefore influence NR response — a factor not yet measured in routine practice.

  • Pre-existing health conditions: Individuals with severe liver or kidney impairment may metabolize NR differently, potentially altering both efficacy and safety.

Potential Risks & Side Effects

A dedicated search for nicotinamide riboside’s side effect profile was performed using PubMed, ClinicalTrials.gov safety reports, drugs.com, expert sources, and Examine.com before writing this section.

High 🟥 🟥 🟥

None Identified

No high-evidence risks (e.g., consistent serious-adverse-event signals across multiple large RCTs) have been identified for nicotinamide riboside at studied doses to date.

Magnitude: Not quantified in available studies.

Medium 🟥 🟥

Theoretical and Preclinical Cancer-Promotion Signal ⚠️ Conflicted

A 2019 study and a follow-up pilot experiment in mice with triple-negative breast cancer reported that NR supplementation accelerated tumor growth and metastasis in the context of pre-existing cancer. Subsequent expert commentary (notably from Peter Attia) has emphasized that the data do not suggest NR initiates cancer, but that NR may act as a metabolic substrate for cancer cells already present. No human RCT has prospectively assessed cancer outcomes, and ongoing oncology trials of NR (e.g., breast-cancer cardio-protection) remain limited. Several oncologists therefore recommend caution in adults with active or recent cancer, particularly while on PARP inhibitors (drugs that exploit NAD+ depletion to kill cancer cells).

Magnitude: Approximately 15% increase in tumor growth in one pilot mouse model of triple-negative breast cancer; no human cancer-incidence data.

Low 🟥

Mild Gastrointestinal Symptoms

Across multiple RCTs, the most common adverse events on NR are mild and transient gastrointestinal (GI, relating to the stomach and intestines) complaints — nausea, indigestion, bloating, and diarrhea. Even at high doses (up to 2,000 mg/day in COPD, 3,000 mg/day in Parkinson’s safety trials), serious treatment-related events have not been reported, and discontinuation rates due to GI symptoms are low.

Magnitude: Incidence comparable to placebo in most trials; symptoms generally mild and self-limiting within 1–2 weeks of starting.

Elevated NAD+ Methylation Burden

NR is metabolized through pathways that consume methyl groups. Theoretical concerns exist that high-dose chronic supplementation could increase methylation demand and stress one-carbon metabolism, particularly in individuals with low folate, B12, or betaine intake or with MTHFR (methylenetetrahydrofolate reductase, an enzyme central to folate metabolism) variants. Direct human evidence of clinically meaningful methylation depletion at typical NR doses is lacking.

Magnitude: Not quantified in available studies.

Skin Flushing and Pruritus

Some individuals experience mild skin flushing or itching at higher NR doses, similar to but generally less pronounced than nicotinic-acid-induced flushing. The 2023 NR-SAFE high-dose Parkinson’s trial reported tolerability at 3,000 mg/day but noted occasional cutaneous reactions.

Magnitude: Not quantified in available studies.

Microbial-Metabolism Effects

The 2026 Christen et al. RCT showed NR (and NMN) feed gut microbial metabolism through conversion to nicotinic acid, with measurable effects on the whole-blood NAD+ metabolome and on microbial growth ex vivo. Whether this is harmful, neutral, or beneficial in chronic use is not yet known.

Magnitude: Not quantified in available studies.

Speculative 🟨

Long-Term Safety Beyond One Year

The longest published NR human trials run to 6–12 months. Multi-year safety data, including effects on cancer incidence, cardiovascular outcomes, or all-cause mortality, are not available. This is a genuine evidentiary gap rather than evidence of harm, but it is highly relevant for an intervention intended for indefinite longevity-oriented use.

Interaction with Active Cancer Treatment

Because NAD+ supports DNA repair and cellular energetics, NR could theoretically reduce the effectiveness of therapies that work by inducing DNA damage or NAD+ depletion (e.g., PARP inhibitors, certain chemotherapies, radiotherapy). Clinical evidence quantifying any such interaction is not yet available.

Risk-Modifying Factors

  • Genetic polymorphisms: Variants affecting one-carbon metabolism (MTHFR), NAD+ catabolism (CD38), and NAD+ utilization (PARP1, SIRT1) could in principle modulate NR’s risk profile, although direct clinical data on how these variants change adverse-event rates are limited.

  • Baseline biomarker levels: Individuals with elevated liver enzymes (ALT, alanine aminotransferase; AST, aspartate aminotransferase — both liver enzymes), abnormal kidney function (low eGFR, estimated glomerular filtration rate, a kidney-function index), or low folate / B12 status warrant more careful monitoring on NR.

  • Sex-based differences: Sex-specific NR adverse-event signals have not been clearly identified, although the NR clinical-trial population overall has been predominantly weighted toward older adults and chronic-disease cohorts.

  • Pre-existing health conditions: Active or recent cancer (especially breast cancer), severe liver or kidney disease, and ongoing chemotherapy with PARP inhibitors are the conditions most likely to alter the risk profile.

  • Age-related considerations: Older adults (>65) may have reduced renal and hepatic clearance of NR metabolites and a higher background prevalence of subclinical malignancy. The cancer-promotion signal is therefore particularly relevant in this age group, where periodic age-appropriate cancer screening is important.

Key Interactions & Contraindications

Prescription drug interactions:

  • PARP inhibitors (olaparib, niraparib, talazoparib): NR-driven NAD+ elevation could theoretically counteract the mechanism of PARP inhibitors. Severity: absolute contraindication during active therapy. Mitigating action: discontinue NR before and during PARP-inhibitor therapy, resume only with oncology guidance.
  • Cytotoxic chemotherapy and radiotherapy: Theoretical concern that improved DNA repair could reduce treatment efficacy. Severity: caution. Mitigating action: discontinue NR during active treatment unless an oncologist explicitly approves continuation.
  • Antihypertensive medications (ACE inhibitors such as lisinopril; ARBs such as losartan; calcium channel blockers such as amlodipine): Possible mild additive blood-pressure lowering. Severity: caution and monitor. Mitigating action: monitor blood pressure after starting NR.
  • Diabetes medications (insulin, metformin, sulfonylureas such as glipizide): NR may modestly influence glucose metabolism; theoretical risk of hypoglycemia (abnormally low blood sugar) when combined with insulin or sulfonylureas, though not clearly observed in trials. Severity: caution and monitor. Mitigating action: monitor fasting and postprandial glucose during the first 4–8 weeks.

Over-the-counter medication interactions:

  • High-dose niacin or nicotinamide: Combining high-dose nicotinic acid (≥500 mg) with NR could amplify methylation burden and flushing. Severity: caution. Mitigating action: avoid concurrent high-dose niacin or separate dosing and monitor.

Supplement interactions:

  • NMN and other NAD+ precursors: NR and NMN feed the same NAD+ pathways with additive effect. Severity: caution. Clinical consequence: cumulative methylation burden and excessive NAD+ pathway loading. Mitigating action: consider total cumulative NAD+ precursor intake rather than stacking maximal doses of each.
  • Pterostilbene: Often co-formulated with NR (e.g., Basis, Niagen+). Severity: caution and monitor. Clinical consequence: possible mild adverse lipid-panel effects at higher pterostilbene doses. Mitigating action: evaluate combined products as a unit and monitor lipid panel.
  • Resveratrol: Frequently combined with NR on the rationale that NR provides NAD+ “fuel” while resveratrol activates SIRT1 (sirtuin 1, a NAD+-dependent enzyme regulating metabolism and stress response). Severity: monitor. Clinical consequence: unconfirmed clinical synergy and the established hepatotoxicity risk of high-dose resveratrol. Mitigating action: keep resveratrol within studied dose ranges and monitor liver enzymes.
  • Apigenin and quercetin: Flavonoids that inhibit CD38 and may enhance NAD+ retention when paired with NR. Severity: monitor. Clinical consequence: amplified NAD+ pathway activity of unquantified clinical magnitude. Mitigating action: avoid stacking maximal doses of multiple CD38 inhibitors.
  • Trimethylglycine (betaine) and methyl donors (B12, folate, choline): May offset theoretical methylation burden of high-dose NR. Severity: monitor (generally favorable interaction). Clinical consequence: supports methylation status; very high methyl-donor intake may modestly raise blood pressure in salt-sensitive individuals. Mitigating action: maintain adequate but not excessive methyl-donor intake.

Other intervention interactions:

  • Intermittent fasting and caloric restriction: Both modestly raise endogenous NAD+. Severity: monitor (no known harm). Clinical consequence: incremental benefit of layered NR is unstudied. Mitigating action: track subjective response when combining and avoid high NR doses during prolonged fasts without medical oversight.

Populations who should avoid or defer nicotinamide riboside:

  • Pregnant or breastfeeding women (insufficient safety data outside specific trial contexts)
  • Adults with active cancer, particularly breast cancer, or undergoing PARP-inhibitor therapy (absolute contraindication during PARP therapy)
  • Adults with severe liver disease (Child-Pugh Class B or C) without physician oversight
  • Adults with advanced chronic kidney disease (eGFR <30 mL/min/1.73m², CKD or chronic kidney disease, Stage 4 or 5) without physician oversight
  • Children and adolescents (insufficient safety and efficacy data)

Risk Mitigation Strategies

  • Low starting dose with gradual escalation: Begin at 250–300 mg/day for 2–4 weeks before considering higher doses (500–1,000 mg/day). This mitigates GI symptoms and skin flushing.

  • Baseline and follow-up labs for liver and kidney function: Obtain a comprehensive metabolic panel before starting NR, repeat at 3 months, then every 6–12 months, particularly for adults over 60 or with pre-existing conditions. This supports early detection of liver or kidney stress.

  • Take with food, in the morning: Administer NR with breakfast to reduce GI symptoms and align with circadian NAD+ biology, which may also reduce any potential evening sleep disruption.

  • Defer NR around active or recent cancer: Hold NR in adults with active cancer or within 2 years of treatment for malignancies (especially breast cancer), and resume only with oncologist input. This mitigates the preclinical cancer-promotion signal.

  • Discontinue at least 2 weeks before PARP-inhibitor therapy: Pause NR ahead of any planned chemotherapy regimen that includes PARP inhibitors, and consult oncology before resuming. This addresses the absolute contraindication with PARP-inhibitor mechanisms.

  • Support methylation status: Maintain adequate folate, B12, and betaine intake (through diet or a comprehensive B-complex), particularly when running doses ≥1,000 mg/day, to offset the theoretical methylation demand of high-dose NR.

  • Purchase only third-party-tested products: Reputable brands with independent certificates of analysis (COA) reduce the risk of underdosed or mislabeled product, given documented underdosing of many NR products in independent testing.

  • Monitor and report persistent side effects: Track flushing, GI symptoms, and any new symptoms; consider dose reduction or discontinuation if persistent.

Therapeutic Protocol

The most commonly studied NR supplementation protocols for healthy adults aged 45–65 are derived from published clinical trials and practitioner guidance. Within the longevity-medicine community, competing therapeutic stances exist: David Sinclair, PhD, has popularized NAD+ precursor supplementation broadly (typically as part of a stack with resveratrol and metformin), while Peter Attia, MD, has been skeptical of routine NR use given limited human efficacy data and the new cancer-promotion concern. Both perspectives are part of the current scientific dialogue.

  • Standard dose: 250–300 mg/day for general health optimization is the lowest effective dose shown to elevate NAD+. 500–1,000 mg/day reflects the dose used in the majority of efficacy RCTs (including the NICE PAD trial). Up to 2,000 mg/day has been used safely in COPD trials, and 3,000 mg/day was tolerated short-term in Parkinson’s safety studies. Higher doses lack long-term safety data.

  • Best time of day: Take in the morning, ideally with breakfast. Morning dosing aligns with circadian NAD+ biology (NAMPT expression peaks during the active phase) and may reduce the chance of evening sleep disruption.

  • Administration form: Oral capsules of NR chloride (Niagen) are the most studied form. Sublingual or liposomal formulations are marketed as enhanced-absorption alternatives but lack head-to-head pharmacokinetic comparisons in published RCTs.

  • Half-life and pharmacokinetics: NR itself is rapidly absorbed and cleared from plasma within hours; whole-blood NAD+ elevation persists for approximately 8–24 hours, supporting once-daily dosing.

  • Single vs. split dosing: Once-daily morning dosing is the standard approach in trials. Split dosing has not been formally compared and is not generally needed given the duration of NAD+ elevation.

  • Genetic considerations: Variants in NRK1/NRK2 may theoretically affect NR-to-NAD+ conversion. APOE4 (a variant of the apolipoprotein E gene associated with elevated Alzheimer’s risk), MTHFR, and COMT (catechol-O-methyltransferase, an enzyme involved in methylation) variants are not directly tied to NR response but may interact with broader longevity-supplement protocols. Pharmacogenomic dose adjustment is not standard practice.

  • Sex-based differences: No clinically established sex-specific dosing exists. Several positive trials have been mixed-sex; some (Werner syndrome, postmenopausal cohorts) have been weighted toward women.

  • Age-related considerations: Adults over 60 may benefit from starting at the low end (250–300 mg/day) given the higher background prevalence of subclinical kidney impairment and the cancer-screening considerations relevant in this age range. The strongest functional benefit signals (PAD, COPD) come from older-adult cohorts.

  • Baseline biomarker levels: Individuals with documented low NAD+ (via specialized testing) or with elevated inflammatory markers (e.g., hsCRP, IL-6) appear in observational data more likely to respond. Routine NAD+ testing is not yet clinical standard.

  • Pre-existing health conditions: In clinical practice, individuals with metabolic syndrome typically start at lower doses with closer glucose monitoring; those with liver or kidney disease initiate only with physician oversight; and those with personal or strong family history of cancer typically defer or discuss with their physician.

Discontinuation & Cycling

  • Long-term vs. short-term use: NR supplementation is generally framed as long-term in longevity contexts, since age-related NAD+ decline is ongoing. There is no established endpoint for discontinuation in healthy adults.

  • Withdrawal effects: No formal withdrawal syndrome has been documented in clinical trials. Whole-blood NAD+ levels gradually return toward baseline over days to weeks after stopping.

  • Tapering protocol: Tapering is not considered necessary; NR can be stopped abruptly without known adverse effects.

  • Cycling: There is no clear evidence that cycling (e.g., 5 days on / 2 days off, or 8 weeks on / 4 weeks off) maintains efficacy or reduces theoretical risks. Some practitioners advocate periodic breaks based on the theoretical concern that chronic NAD+ elevation might downregulate endogenous NAD+ biosynthesis or, given the preclinical cancer signal, that periodic washout may be prudent. Most clinical trials used continuous daily dosing without cycling.

Sourcing and Quality

Sourcing, purity, and formulation are particularly important for nicotinamide riboside because the NR consumer market has been volatile. ConsumerLab’s most recent NR review notes that several NR products do not match labeled potency. Conflict of interest note: Most public-facing NR efficacy and quality information is generated by parties with a direct financial interest — including ChromaDex (Niagen ingredient supplier), Tru Niagen, Elysium Health (Basis), Niagen Bioscience, and licensed retail brands — many of whom have funded the human trials cited in this review. Brand and ingredient endorsements should be read in that context.

  • Third-party testing: Products that publish independent certificates of analysis (COA) verifying ≥98% NR purity and matching labeled potency are preferred in clinical practice.

  • GMP certification: Products manufactured in FDA-registered, GMP (Good Manufacturing Practice) certified facilities offer greater quality assurance than uncertified manufacturers.

  • Validated raw ingredients: Niagen (NR chloride from ChromaDex) is the most clinically validated NR ingredient, used in the majority of human trials. Niagen+ and Tru Niagen are licensed retail products built around this ingredient.

  • Stability and storage: NR chloride is hygroscopic (absorbs moisture) and somewhat heat-sensitive. Products should be stored in a cool, dry place, with the bottle tightly sealed; refrigeration may extend shelf life for opened bottles.

  • Combination products: Elysium Basis combines NR with pterostilbene; some products combine NR with resveratrol, quercetin, or apigenin. Combinations should be evaluated on the merits of every ingredient, not only the NR content.

  • Forms available: Oral capsules and tablets of NR chloride dominate the market and are the form used in clinical trials. Sublingual powders, liposomal formulations, and intravenous infusions are also marketed; intravenous NR / NAD+ products have not been validated against oral NR in controlled outcome trials.

Practical Considerations

  • Time to effect: Whole-blood NAD+ rises within hours of the first dose and reaches steady-state elevation within 1–2 weeks. Functional or symptomatic benefits — where they appear — typically take 4–12 weeks of consistent supplementation.

  • Common pitfalls: Buying low-quality or counterfeit NR without third-party verification; expecting dramatic, immediately noticeable effects when NR’s effects are typically subtle and biomarker-level; using high doses (≥1,500 mg/day) chronically without long-term safety data; failing to pause NR around cancer treatment; neglecting baseline and follow-up labs.

  • Regulatory status: In the United States, NR (as Niagen) was self-affirmed GRAS in 2015, FDA-acknowledged as a New Dietary Ingredient (NDI), and is widely sold as a dietary supplement. NR is not approved as a drug for any indication. In the European Union, NR has Novel Food authorization. Marketing claims for longevity or disease prevention are not approved by the FDA.

  • Cost and accessibility: NR is moderately expensive relative to common supplements. A 30-day supply at 300 mg/day from a reputable brand typically costs $30–$60 USD; 1,000 mg/day formulations and combination products (e.g., Basis) cost more, often $60–$100/month. NR is widely available from major US retailers and direct-to-consumer brands.

Interaction with Foundational Habits

  • Sleep: Direct, generally neutral. NR has been associated with modest sleep-quality improvements in exploratory analyses (e.g., Wu et al., 2025 in long-COVID), although primary endpoints in dedicated sleep trials have not been clearly positive. Some individuals report difficulty sleeping when NR is taken in the late afternoon or evening, possibly due to increased cellular energy metabolism. Practical consideration: take in the morning rather than evening.

  • Nutrition: Indirect, supportive. NR occurs naturally in trace amounts in milk, yeast, and some foods, but dietary amounts are far below supplementation doses. NR metabolism consumes methyl groups, so adequate folate, B12, and choline / betaine intake helps offset the theoretical methylation burden of higher doses. Practical consideration: take NR with food to improve GI tolerance and ensure adequate methyl-donor nutrition.

  • Exercise: Direct, potentiating. NR enhanced 6-minute walking distance in PAD (NICE trial) and is often combined with structured exercise in active trials (e.g., NCT06425042; Friedreich ataxia 2026). NAD+ is essential for mitochondrial energy production, and there is no current evidence that NR blunts training adaptations (in contrast to high-dose antioxidants such as vitamin C/E megadoses, which can impair certain adaptations). Practical consideration: morning dosing fits well with most exercise schedules; pairing NR with progressive aerobic and resistance training is reasonable.

  • Stress management: Indirect, supportive. NAD+ supports the cellular stress response via SIRT1 and PARP activation, and chronic stress consumes NAD+ via PARP-mediated DNA repair. NR may help maintain NAD+ pools under chronic stress, but direct effects on cortisol (the body’s primary stress hormone) have not been demonstrated. Practical consideration: NR is not a substitute for sleep, social connection, or stress-management practices and is best layered on top of them.

Monitoring Protocol & Defining Success

Baseline laboratory testing is performed in clinical practice before initiating NR supplementation to establish reference values, screen for contraindications (e.g., subclinical liver or kidney disease, dyslipidemia), and enable meaningful interpretation of subsequent measurements.

Ongoing monitoring follows a cadence of repeat testing at 3 months after starting, then every 6–12 months during continued supplementation. Adults over 60 or with pre-existing conditions may benefit from more frequent monitoring (every 3–6 months).

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Whole-blood NAD+ (intracellular) >40 µM Directly measures the molecule NR aims to elevate Specialized assay (e.g., Jinfiniti Diagnostics); not routinely available at standard labs. A standard comprehensive metabolic panel (CMP) does not include NAD+. Fasting sample preferred.
Comprehensive Metabolic Panel (CMP) Standard reference ranges Screens liver and kidney function, glucose, electrolytes for safety monitoring CMP = a standard blood chemistry panel. Fasting for 8–12 hours required.
ALT 7–35 U/L (functional: <25 U/L) Monitors for hepatocellular stress ALT = alanine aminotransferase, a liver enzyme. Functional medicine targets ALT <25 U/L; conventional upper limit is 35–40 U/L.
AST 10–35 U/L (functional: <25 U/L) Monitors for hepatocellular stress; elevated alongside ALT suggests liver injury AST = aspartate aminotransferase. Can also rise after intense exercise; time blood draw >48 hours after strenuous activity.
Creatinine / eGFR eGFR >90 mL/min/1.73m² Monitors kidney function eGFR = estimated glomerular filtration rate. Conventional “normal” is >60; functional range is >90.
Fasting glucose 72–85 mg/dL (functional) Tracks metabolic response Conventional normal is 70–99 mg/dL. 8–12 hour fast required.
HbA1c 4.8–5.2% (functional) Longer-term metabolic monitoring HbA1c = glycated hemoglobin, a marker of long-term blood sugar control. Conventional “normal” is <5.7%; functional optimal is <5.2%. No fasting required.
Fasting lipid panel Total cholesterol <200; LDL <100; HDL >60; TG <100 mg/dL Tracks any lipid effects of combined NAD+-precursor / pterostilbene products LDL = low-density lipoprotein; HDL = high-density lipoprotein; TG = triglycerides. Fasting for 12 hours recommended. Functional triglyceride target <100 vs. conventional <150 mg/dL.
hs-CRP <1.0 mg/L (functional) Tracks systemic inflammation, a domain in which NR has shown signals of effect hs-CRP = high-sensitivity C-reactive protein, a general marker of systemic inflammation. Testing during acute illness should be avoided as it can transiently elevate hs-CRP.
Homocysteine 5–8 µmol/L (functional) Screens for methylation status, relevant given NR’s methyl-group consumption at higher doses Conventional upper limit is 15 µmol/L; functional medicine prefers <8. Fasting preferred.

Qualitative markers to track:

  • Energy levels throughout the day (sustained vs. afternoon crashes)
  • Sleep quality (time to fall asleep, number of awakenings, feeling rested upon waking)
  • Cognitive clarity and focus
  • Exercise endurance and recovery time
  • Walking endurance, particularly in adults with PAD or other vascular limitations
  • Skin quality and appearance
  • Overall sense of vitality and well-being

Emerging Research

Several active clinical trials and emerging research directions are likely to advance the understanding of nicotinamide riboside over the next several years.

Conclusion

Nicotinamide riboside is a well-characterized vitamin B3 derivative that reliably raises blood levels of a central cellular fuel and helper coenzyme in adults. Short-term safety in trials of up to 6–12 months is reassuring across doses from a few hundred milligrams to several grams per day. Beyond NAD+ elevation, the most consistent clinical signals are reductions in airway and hepatic inflammation in specific chronic conditions, improved walking distance in peripheral artery disease, modest reductions in an Alzheimer’s-related blood biomarker without measurable cognitive improvement, and disease-modifying effects in the rare progeroid disorder Werner syndrome.

For broader healthy-aging endpoints — muscle strength, gait, general cognition, blood pressure, and metabolic markers — the human evidence is heterogeneous and often null. Pooled meta-analyses temper the enthusiasm of individual positive trials, especially in skeletal muscle outcomes. Two further considerations weigh on the picture: a preclinical signal that nicotinamide riboside may accelerate growth of pre-existing tumors in some cancer models, and the absence of multi-year human safety data.

A meaningful share of nicotinamide riboside efficacy and product evidence is generated by parties with a direct financial interest in its adoption — ingredient suppliers and finished-product brands that have funded many of the human trials — and that conflict of interest tempers how independently strong the current case can be considered. For longevity-oriented adults already attending to sleep, nutrition, exercise, and stress management, nicotinamide riboside occupies a plausible but not yet conclusively proven position in the supplement landscape.

Top - Benefits - Risks - Protocol